I always felt they didn't have enough respect for the processes which the FDA follows. Poorly designed trials rather than failure of what their biotech. Most unfortunate for shareholders and also for their potential patient base.
AII NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors
